首页> 美国卫生研究院文献>Journal of Asthma and Allergy >Sesame allergy: current perspectives
【2h】

Sesame allergy: current perspectives

机译:芝麻过敏:当前观点

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Sesame is an important global allergen affecting ~0.1% of the North American population. It is a major cause of anaphylaxis in the Middle East and is the third most common food allergen in Israel. We conducted a systematic review of original articles published in the last 10 years regarding the diagnosis and management of sesame allergy. Skin prick testing appears to be a useful predictor of sesame allergy in infants, although data are less consistent in older children and adults. The diagnostic capacity of serum-specific immunoglobulin E is poor, especially in studies that used oral food challenges to confirm the diagnosis. Double-blind, placebo-controlled food challenge thus remains the diagnostic gold standard for sesame allergy. The cornerstone of sesame allergy management is allergen avoidance, though accidental exposures are common and patients must be prepared to treat the consequent reactions with epinephrine. Novel diagnostic and treatment options such as component-resolved diagnostics, basophil activation testing, and oral immunotherapy are under development but are not ready for mainstream clinical application.
机译:芝麻是一种重要的全球性过敏原,约占北美人口的0.1%。它是中东地区过敏反应的主要原因,并且是以色列第三大最常见的食物过敏原。我们对过去十年中有关芝麻过敏的诊断和处理的原始文章进行了系统的综述。皮肤点刺试验似乎是婴儿芝麻过敏的有用预测指标,尽管年龄较大的儿童和成人的数据不一致。血清特异性免疫球蛋白E的诊断能力很差,尤其是在使用口服食品挑战确认诊断的研究中。因此,双盲,安慰剂控制的食物挑战仍然是芝麻过敏的诊断金标准。芝麻过敏处理的基石是避免过敏原,尽管意外暴露很常见,患者必须准备好用肾上腺素治疗随之产生的反应。新型的诊断和治疗选择,例如组分分辨诊断,嗜碱性粒细胞活化测试和口服免疫疗法,正在开发中,但尚未准备好用于主流临床应用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号